NCT00048581 - Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. | Biotech Hunter

Enrollment

738

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Abatacept

Vials, intravenous (IV), \~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.

DRUG

Placebo

Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.

DRUG

Abatacept

Vials, IV, \~10mg/kg abatacept, every 4 weeks, 5.5 years

Trial Locations (42)

Unknown

Local Institution, Birmingham

Local Institution, Mobile

Local Institution, Paradise Valley

Local Institution, La Jolla

Local Institution, Long Beach

Local Institution, Palo Alto

Local Institution, Rancho Mirage

Local Institution, Denver

Local Institution, Englewood

Local Institution, Bridgeport

Local Institution, Hamden

Local Institution, Clearwater

Local Institution, Fort Lauderdale

Local Institution, Largo

Local Institution, Palm Harbor

Local Institution, Tampa

Local Institution, Rome

Local Institution, Indianapolis

Local Institution, Wichita

Local Institution, New Orleans

Local Institution, Boston

Local Institution, Springfield

Local Institution, Lincoln

Local Institution, New Brunswick

Local Institution, Albany

Local Institution, Syracuse

Local Institution, Charlotte

Local Institution, Hickory

Local Institution, Bismarck

Local Institution, Cincinnati

Local Institution, Oklahoma City

Local Institution, Eugene

Local Institution, Portland

Local Institution, Duncansville

Local Institution, Norristown

Local Institution, Sellersville

Local Institution, Willow Grove

Local Institution, Charleston

Local Institution, Austin

Local Institution, Dallas

Local Institution, Vancouver

Local Institution, Milwaukee